Journal
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY
Volume 79, Issue 1, Pages -Publisher
WILEY
DOI: 10.1111/aji.12785
Keywords
angiogenic; antiphospholipid antibody; chemokine; endothelium; pregnancy
Categories
Funding
- Albert Einstein College of Medicine, Yeshiva University
- American Heart Association [15GRNT24480140]
- National Center for Advancing Translational Sciences [TL1TR000141]
Ask authors/readers for more resources
ProblemWomen with antiphospholipid antibodies (aPL) are at risk for pregnancy complications despite treatment with low molecular weight heparin (LMWH) or aspirin (ASA). aPL recognizing beta(2) glycoprotein I can target the uterine endothelium, however, little is known about its response to aPL. This study characterized the effect of aPL on human endometrial endothelial cells (HEECs), and the influence of LMWH and ASA. Method of studyHEECs were exposed to aPL or control IgG, with or without low-dose LMWH and ASA, alone or in combination. Chemokine and angiogenic factor secretion were measured by ELISA. A tube formation assay was used to measure angiogenesis. ResultsaPL increased HEEC secretion of pro-angiogenic VEGF and PlGF; increased anti-angiogenic sFlt-1; inhibited basal secretion of the chemokines MCP-1, G-CSF, and GRO-; and impaired angiogenesis. LMWH and ASA, alone and in combination, exacerbated the aPL-induced changes in the HEEC angiogenic factor and chemokine profile. There was no reversal of the aPL inhibition of HEEC angiogenesis by either single or combination therapy. ConclusionBy aPL inhibiting HEEC chemokine secretion and promoting sFlt-1 release, the uterine endothelium may contribute to impaired placentation and vascular transformation. LMWH and ASA may further contribute to endothelium dysfunction in women with obstetric APS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available